Long-term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer

TAKAHIRO EINAMA1,3*, HIRONORI ABE1*, SHUNSUKE SHICHI1, HIROKI MATSUI1, RYO KANAZAWA1, KAZUAKI SHIBUYA1, TAKASHI SUZUKI1, FUMIHIKO MATSUZAWA1, TAKU HASHIMOTO1, NAKACHI KOHEI2, SHIGENORI HOMMA3, HIDEKI KAWAMURA3 and AKINOBU TAKETOMI3

Departments of 1Surgery and 2Internal Gastroenterology, Hokkaido Social Work Association Obihiro Hospital, Obihiro, Hokkaido 080-0805; 3Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan

Received May 18, 2016; Accepted November 23, 2016

DOI: 10.3892/mco.2017.1128

Abstract. In gastric cancer, primary systemic chemotherapy is the standard approach for the management of patients with initially unresectable metastasis, and it occasionally leads to a reduction in the size of the lesion, which facilitates surgical resection. The aim of this study was to examine the prognosis of patients who were able to undergo complete resection following chemotherapy. A total of 10 patients who underwent radical surgery for stage IV primary gastric cancer after chemotherapy between 2009 and 2015 at the Department of Surgery of Hokkaido Social Work Association Obihiro Hospital (Obihiro, Japan) were retrospectively investigated. Three regimens were used (S-1, n=1; S-1 + cisplatin, n=8; and S-1 + docetaxel, n=1). The mean time from chemotherapy to surgery was 210 days. One total gastrectomy + splenectomy + colectomy, one total gastrectomy + splenectomy, four total gastrectomies and three distal gastrectomies were performed. There were two cases of pancreatic fistula formation postoperatively. All the patients survived for >1 year. Of the 10 patients, 5 survived without recurrence. The median survival time was 871.1 days after diagnosis. Therefore, curative resection after chemotherapy is associated with a better prognosis in stage IV gastric cancer patients.

Introduction

Gastric cancer is the second most prevalent malignancy worldwide (1). With the advances in chemotherapy, a standard treatment for gastric cancer has been established and it has been published in the Japanese treatment guidelines for gastric cancer (2). Certain randomized controlled trials have reported improved patient survival, but the median survival time (MST) is limited to 13-16 months (3-7). Therefore, novel therapeutic approaches should be considered to improve the survival of stage IV gastric cancer patients.

Recently, the response rate to new chemotherapy regimens has improved markedly, whereas the role of surgery for stage IV gastric cancer patients responsive to induction chemotherapy remains fairly uncertain. Performing surgery in such patients may result in a survival benefit following curative resection. This type of surgery is referred to as conversion surgery. However, the clinical value of conversion surgery for stage IV gastric cancer remains controversial.

The aim of this study was to retrospectively evaluate conversion surgery for stage IV gastric cancer patients in terms of operative morbidity, mortality, prognostic factors, recurrence and overall survival.

Patients and methods

Patients. This study was performed with the approval of the Internal Review Board on Ethical Issues of the Hokkaido Social Work Association Obihiro Hospital. Patients diagnosed with stage IV gastric cancer who underwent chemotherapy in our hospital between January, 2009 and December, 2015 were retrospectively reviewed. The inclusion criteria were as follows: i) Histologically confirmed gastric cancer; ii) distant metastatic sites confirmed by computed tomography and/or positron emission tomography; iii) patient receiving a chemotherapeutic regimen for at least one cycle; iv) Eastern Cooperative Oncology Group performance status of 0 or 1; and v) no history of prior chemotherapy or radiotherapy. Surgery was then performed within 5-6 weeks after the last cycle of chemotherapy.

A total of 10 patients underwent conversion surgery for stage IV gastric cancer (Table I). The patients were also stratified into two categories, according to recurrence after conversion surgery (recurrence or non-recurrence groups) and according to the histological type [differentiated-type
(well- or moderately differentiated tubular adenocarcinoma, tub1 and tub2, respectively), and undifferentiated-type (poorly differentiated or signet ring cell carcinoma, por and sig, respectively).

Treatment regimen. The chemotherapeutic regimens were as follows: 1 patient was assigned to receive S-1 (S-1 case) administered at a dose of 80 mg/m²/day divided into two daily doses for 28 days, followed by 14 days of rest; 8 patients were assigned to S-1 plus cisplatin (CDDP) and received oral S-1 (80 mg/m²/day divided into two daily doses for 21 days) plus intravenous CDDP (60 mg/m² on day 8) repeated every 5 weeks; and 1 patient was assigned to the S-1 plus docetaxel (DOC) group and received oral S-1 (80 mg/m²/day divided into two daily doses for 14 days) plus intravenous DOC (40 mg/m² on day 1) repeated every 3 weeks.

Follow-up schedule. Physical examinations and laboratory tests were performed every 2 weeks during the treatments. Tumor response was evaluated by computed tomography every 4-8 weeks using the Response Evaluation Criteria In Solid Tumors guidelines (8).

Indications for conversion surgery. Candidates for conversion surgery were those for whom R0 resection could be achieved on the basis of the response to chemotherapy, if there were no non-curative factors. The majority of the patients received adjuvant chemotherapy, mainly with S-1.

Results

Characteristics of patients undergoing conversion surgery. The preoperative characteristics of the 10 patients who

Table I. Characteristics of the 10 gastric cancer patients who underwent conversion surgery.

| Case | Age (years) | Gender | Incurable factor | Histopathological type | Macroscopic type | Preoperative chemotherapy | Period of chemotherapy (days) |
|------|-------------|--------|-----------------|------------------------|-----------------|--------------------------|-------------------------------|
| 1    | 85          | M      | LNM             | tub2                   | 2               | S-1                      | 213                           |
| 2    | 70          | M      | LNM             | tub2-por              | 2               | S-1+CDDP                | 500                           |
| 3    | 72          | M      | LNM             | tub2-por              | 2               | S-1+CDDP                | 143                           |
| 4    | 74          | M      | LM              | tub1>tub2>por         | 2               | S-1+CDDP                | 136                           |
| 5    | 69          | M      | CY              | sig>por               | 5               | S-1+CDDP                | 133                           |
| 6    | 81          | F      | PM              | por-sig               | 3               | S-1+DOC                 | 150                           |
| 7    | 63          | F      | PM              | por>tub2              | 3               | S-1+CDDP                | 123                           |
| 8    | 60          | M      | LNM             | por                    | 3               | S-1+CDDP                | 95                            |
| 9    | 59          | M      | Other organ invasion (colon) | tub1-tub2   | 4               | S-1+CDDP                | 139                           |
| 10   | 72          | F      | LNM             | tub1-tub2              | 4               | S-1+CDDP                | 467                           |

M, male; F, female; LNM, lymph node metastasis; LM, liver metastasis; PM, peritoneal metastasis; CDDP, cisplatin; CY, cytology; DOC, docetaxel; tub1, well-differentiated tubular adenocarcinoma; tub2, moderately differentiated tubular adenocarcinoma; por, poorly differentiated adenocarcinoma; sig, signet ring cell carcinoma.

Table II. Demographics of conversion surgery for gastric cancer and postoperative outcome.

| Case | Operation | Postoperative complications | Postoperative chemotherapy | Pathological response | Recurrence region | DFS (days) | OS (days) | Patient status |
|------|-----------|-----------------------------|-----------------------------|-----------------------|-------------------|------------|-----------|---------------|
| 1    | TG + SC   | None                        | None                        | 1b                    | None             | 1,417      | Alive     |               |
| 2    | DG        | None                        | S-1                         | 1a                    | None             | 1,178      | Alive     |               |
| 3    | TG        | None                        | S-1                         | 1a                    | None             | 1,385      | Alive     |               |
| 4    | DG + Hr0  | None                        | S-1                         | 1b                    | None             | 920        | Alive     |               |
| 5    | TG        | None                        | CY+                         | 2                     | None             | 515        | Alive     |               |
| 6    | TG + SC   | None                        | None                        | 1b                    | Peritoneal       | 174        | 406       | Dead         |
| 7    | DG + Hr0 + P | None                    | S-1 + CDDP                | 1b                    | Liver            | 75         | 430       | Dead         |
| 8    | DG        | None                        | S-1 + CDDP                | 1a                    | Lymph node       | 333        | 672       | Dead         |
| 9    | TG + SC + colectomy | Pancreatic fistula | S-1                         | 1a                    | Liver            | 839        | 1,090     | Dead         |
| 10   | TG        | None                        | S-1                         | 3                     | Lymph node       | 511        | 1,175     | Alive        |

DFS, disease-free survival; OS, overall survival; TG, total gastrectomy; SC, splenectomy; DG, distal gastrectomy; Hr, hepatic resection; P, peritoneal resection; CDDP, cisplatin; CY, cytology.

(well- or moderately differentiated tubular adenocarcinoma, tub1 and tub2, respectively), and undifferentiated-type (poorly differentiated or signet ring cell carcinoma, por and sig, respectively).
underwent conversion surgery are summarized in Table I. The patients included 8 men and 2 women with a median age of 70.5 years (range, 59-86 years). All 10 patients had one incurable factor prior to chemotherapy: 1 patient had T4b, 3 had P1, 1 had H1, 4 had M1 (distant lymph node metastasis) and 1 had CY1 disease. All the patients were assessable regarding their response. After chemotherapy, all the cases were considered as resectable gastric cancer, achieving R0 resection. The median interval between diagnosis and surgery was 210 days (range, 95-500 days).

Three regimens were used (S-1, n=1; S-1 + CDDP, n=8; and S-1 + DOC, n=1). One total gastrectomy + splenectomy + colectomy, one total gastrectomy+splenectomy, four total gastrectomies and three distal gastrectomies were performed. There were 2 cases of pancreatic fistula postoperatively. All the patients survived for >1 year after the diagnosis. Of the 10 patients, 5 survived without recurrence. The median survival time was 871.1 days after diagnosis (Table II).

Comparison between the recurrence and non-recurrence groups. In the recurrence group, the metastatic sites included 2 peritoneal disseminations, 1 multiple visceral invasion and 2 lymph node metastases prior to chemotherapy. In the non-recurrence group, the metastatic sites included 1 case of positive peritoneal cytology, 1 case of liver metastasis and 3 cases of lymph node metastasis prior to surgery. The pathological findings prior to chemotherapy were 3 undifferentiated-type and 2 differentiated-type patients in the recurrence group, and 1 undifferentiated-type and 4 differentiated-type patients in the non-recurrence group (Table III).

Discussion

According to the Japanese guidelines for gastric cancer (2), S-1/CDDP is the standard first-line systemic chemotherapy for human epidermal growth factor (HER)2-negative patients (3), whereas trastuzumab + capecitabine + CDDP (XP regimen) is considered as the first-line treatment for HER2-positive patients (7). More recently, as significant progress has been made by improving chemotherapeutic regimens, conversion surgeries have been performed for stage IV gastric cancer patients (9-14). In colorectal metastases, complete resection was found to achieve a 5-year survival rate of 35-58% (15-17).

Our data revealed that patients who underwent conversion surgery exhibited a longer survival compared with those who received chemotherapy alone, which was consistent with previous findings (10,13,18-20) (Table IV). Furthermore, among patients undergoing conversion surgery, higher differentiation and non-invasive macroscopic type are favorable survival predictors. If chemotherapy leads to a transient response and conversion surgery is achievable, conversion surgery may prolong survival in selected patients.

Based on our data, 3 of 5 cases exhibited the same relapse patterns prior to chemotherapy. In colorectal cancer, macroscopic residual disease was found during surgical exploration at the site of liver metastases that were considered to have disappeared on imaging. In patients without detection of further tumors and in whom the site of the complete response remained intact, in situ recurrence was observed in 74% of the cases after 1 year (21). These data demonstrated that removing the region of metastasis that was present prior to chemotherapy may improve the prognosis with conversion surgery.

All cases with peritoneal dissemination recurred after conversion surgery. In the case of macroscopic peritoneal metastasis, it is insufficient to completely remove macroscopic cancer after conversion surgery. However, such patients exhibited a better prognosis compared with those who were treated with chemotherapy alone, and cytology-positive patients survived without recurrence. S-1 is effective as postoperative chemotherapy for gastric cancer patients with positive peritoneal lavage cytology following macroscopically curative resection (22). According to these results, additional treatments may be required before or after conversion surgery for peritoneal dissemination.

---

Table III. Comparison of recurrence and non-recurrence groups.

| Case | Histopathological type | Macroscopic type |
|------|------------------------|------------------|
| 1    | tub2                   | 2                |
| 2    | tub2-por               | 2                |
| 3    | tub2-por               | 2                |
| 4    | tub1>tub2>por          | 2                |
| 5    | sig>por2               | 5                |

Table IV. Comparison of prognosis in stage IV gastric cancer patients.

| Trial (chemotherapy regimen) | OS (months) | Refs. |
|------------------------------|-------------|-------|
| JCOG9912 (S-1)               | 11.4        | (22)  |
| SPIRITS (SP)                 | 13.0        | (3)   |
| ToGA (HXP)                   | 13.8        | (7)   |
| Our cases (conversion surgery) | 29.0      |       |

OS, overall survival; SP, S-1 + cisplatin; HXP, trastuzumab + capecitabine + cisplatin.

tub1, well-differentiated tubular adenocarcinoma; tub2, moderately differentiated tubular adenocarcinoma; por, poorly differentiated adenocarcinoma; sig, signet ring cell carcinoma.
Therefore, conversion surgery may be associated with a more favorable prognosis in stage IV gastric cancer patients. According to our results, patients without peritoneal dissemination and with more highly differentiated tumors have a better prognosis following conversion surgery.

Acknowledgements

The authors would like to thank all the staff members of the Hokkaido Social Work Association Obihiro Hospital for their kindness and diligence.

References

1. Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol 12: 354-362, 2006.
2. Sano T and Aiko T: New Japanese classifications and treatment guidelines for gastric cancer: Revision concepts and major revised points. Gastric Cancer 14: 97-100, 2011.
3. Kotuzmi W, Narahara H, Haru T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takayami W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 9: 215-221, 2008.
4. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takayami W, Sato Y, Todo S, Terashima M, Gotto M, Sakamoto J and Nishizumi M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402-3407, 2006.
5. Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, et al: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START). J Cancer Res Clin Oncol 140: 319-328, 2014.
6. Tanabe K, Suzuki T, Tokumoto N, Yamamoto H, Yoshida K and Ohdan H: Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: A retrospective analysis. World J Surg Oncol 8: 40, 2010.
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
9. Yoshida K, Yamaguchi K, Okumura N, Osada S, Takahashi T, Tanaka Y, Tanabe K and Suzuki T: The roles of surgical oncoologists in the new era: Minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer. Pathobiology 78: 343-352, 2011.
10. Suzuki T, Tanabe K, Taamoto J, Yamamoto H, Tokumoto N, Yoshida K and Ohdan H: Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett 1: 743-727, 2010.
11. Satoh S, Okabe H, Teramukai S, Hasegawa S, Ozaki N, Ueda S, Tsuji A, Sakabayashi S, Fukushima M and Sakai Y: Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. Gastrointestinal Cancer 13: 61-69, 2012.
12. Han DS, Suh YS, Kong SH, Lee HJ, Im SA, Bang YJ, Kim WH and Yang HK: Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. J Surg Oncol 107: 511-516, 2013.
13. Okabe H, Ueda S, Obama K, Hosogi H and Sakai Y: Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol 16: 3277-3286, 2009.
14. Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, Fukushima M, Takabayashi A and Sakai Y: Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastrointestinal Cancer 9: 129-135, 2006.
15. Martin LW and Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin N Am 9: 853-878, 2000.
16. Penna C and Nordlinger B: Colorectal metastasis (liver and lung). Surg Clin North Am 82: 1075-1090, x-xi, 2002.
17. Abdalla ER, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K and Curley SA: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239: 818-827, 2004.
18. Wang Y, Yu YY, Li W, Feng Y, Hou J, Ji Y, Sun YH, Shen KT, Shen ZB, Qin XY and Liu TS: A phase II trial of Xeloda and oxaliplatin (XELOX) in patients with advanced colorectal liver metastases. World J Gastroenterol 14: 3402-3407, 2008.
19. Ishibashi K, Kuwano H and Mochiki E: Combined resection for colorectal liver metastases: Impact on survival. Gastric Cancer 9: 239-243, 2006.
20. Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, Koijima H, Matsuki T, Kondo K and Fujimura M: Long-term follow-up of patients who were positive for peritoneal lavage cytology: Final report from the CCOG0301 study. Gastric Cancer 15: 335-337, 2012.
21. Fujiuchi M, Ishiguro T, Ogata K, Suzuki O, Kugayagi Y, Ishihashi K, Ishida H, Kuwano H and Mochiki E: Prognostic role of conversion surgery for unresectable gastric cancer. Ann Surg Oncol 22: 3618-3624, 2015.
22. Benoist S, Brouquet A, Penna C, Julié C, El Hajjim M, Chagnon S, Mitry E, Rougier P and Nordlinger B: Complete response of colorectal liver metastases after chemotherapy: Is it meaningful? J Clin Oncol 24: 3939-3945, 2006.
23. Akoh E, Ohira M, Yamashita Y, Kubo N, Muramura K, Yashiro M, Sawada T, Nakata B, Kato Y and Hirakawa K: Efficacy of S-1 for gastric cancer patients with positive peritoneal lavage cytology. Hepatogastroenterology 55: 1939-1942, 2008.